|
1
|
Stupp R, Tonn JC, Brada M and
Pentheroudakis G; ESMO Guidelines Working Group, : High-grade
malignant glioma: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 21 (Suppl 5):v190–v193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schwartzbaum JA, Fisher JL, Aldape KD and
Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin
Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scorsetti M, Navarria P, Pessina F,
Ascolese AM, D'Agostino G, Tomatis S, De Rose F, Villa E, Maggi G,
Simonelli M, et al: Multimodality therapy approaches, local and
systemic treatment, compared with chemotherapy alone in recurrent
glioblastoma. BMC Cancer. 15:4862015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Newlands ES, Stevens MF, Wedge SR,
Wheelhouse RT and Brock C: Temozolomide: A review of its discovery,
chemical properties, pre-clinical development and clinical trials.
Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brock CS, Newlands ES, Wedge SR, Bower M,
Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH and Rustin
GJ: Phase I trial of temozolomide using an extended continuous oral
schedule. Cancer Res. 58:4363–4367. 1998.PubMed/NCBI
|
|
6
|
Tolcher AW, Gerson SL, Denis L, Geyer C,
Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman
L, et al: Marked inactivation of O6-alkylguanine-DNA
alkyltransferase activity with protracted temozolomide schedules.
Br J Cancer. 88:1004–1011. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amakye D, Jagani Z and Dorsch M:
Unraveling the therapeutic potential of the Hedgehog pathway in
cancer. Nat Med. 19:1410–1422. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang K, Chen D, Qian Z, Cui D, Gao L and
Lou M: Hedgehog/Gli1 signaling pathway regulates MGMT expression
and chemoresistance to temozolomide in human glioblastoma. Cancer
Cell Int. 17:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Santoni M, Burattini L, Nabissi M, Morelli
MB, Berardi R, Santoni G and Cascinu S: Essential role of Gli
proteins in glioblastoma multiforme. Curr Protein Pept Sci.
14:133–140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beauchamp EM, Ringer L, Bulut G, Sajwan
KP, Hall MD, Lee YC, Peaceman D, Özdemirli M, Rodriguez O,
Macdonald TJ, et al: Arsenic trioxide inhibits human cancer cell
growth and tumor development in mice by blocking Hedgehog/GLI
pathway. J Clin Invest. 121:148–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang D, Cao F, Ye X, Zhao H, Liu X, Li Y,
Shi C, Wang H and Zhou J: Arsenic trioxide inhibits the hedgehog
pathway which is aberrantly activated in acute promyelocytic
leukemia. Acta Haematol. 130:260–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Breccia M and Lo-Coco F: Arsenic trioxide
for management of acute promyelocytic leukemia: Current evidence on
its role in front-line therapy and recurrent disease. Expert Opin
Pharmacother. 13:1031–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Li H, Chen YY, Wang XJ, Shi GY, Hu
QS, Kang XL, Lu Y, Tang XM, Guo QS and Yi J: Anthraquinones
sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo
via reactive oxygen species-mediated dual regulation of apoptosis.
Free Radic Biol Med. 37:2027–2041. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pettersson HM, Pietras A, Munksgaard
Persson M, Karlsson J, Johansson L, Shoshan MC and Påhlman S:
Arsenic trioxide is highly cytotoxic to small cell lung carcinoma
cells. Mol Cancer Ther. 8:160–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S,
Sun X and Jiang H: Genistein potentiates the effect of arsenic
trioxide against human hepatocellular carcinoma: Role of Akt and
nuclear factor-κB. Cancer Lett. 301:75–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, Qian H, Li Y, Wang Y, Zhang X, Liang
X, Fu M and Lin C: Arsenic trioxide (As2O3)
reduces the invasive and metastatic properties of cervical cancer
cells in vitro and in vivo. Gynecol Oncol. 106:400–406. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maeda H, Hori S, Nishitoh H, Ichijo H,
Ogawa O, Kakehi Y and Kakizuka A: Tumor growth inhibition by
Arsenic Trioxide (As2O3) in the orthotopic
metastasis model of Androgen-independent prostate cancer. Cancer
Res. 61:5432–5440. 2001.PubMed/NCBI
|
|
18
|
Nakamura S, Nagano S, Nagao H, Ishidou Y,
Yokouchi M, Abematsu M, Yamamoto T, Komiya S and Setoguchi T:
Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI
transcription via DNA damage accumulation. PLoS One. 8:e694662013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Subbarayan PR and Ardalan B: In the war
against solid tumors arsenic trioxide needs partners. J
Gastrointest Cancer. 45:363–371. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murgo AJ: Clinical trials of arsenic
trioxide in hematologic and solid tumors: Overview of the national
cancer institute cooperative research and development studies.
Oncologist. 6 (Suppl 2):S22–S28. 2001. View Article : Google Scholar
|
|
21
|
Meiss F and Zeiser R: Vismodegib. Recent
Results Cancer Res. 201:405–417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagao-Kitamoto H, Nagata M, Nagano S,
Kitamoto S, Ishidou Y, Yamamoto T, Nakamura S, Tsuru A, Abematsu M,
Fujimoto Y, et al: GLI2 is a novel therapeutic target for
metastasis of osteosarcoma. Int J Cancer. 136:1276–1284. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mazzucchelli S, Truffi M, Baccarini F,
Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli
A, Ciuffreda P, et al: H-Ferritin-nanocaged olaparib: A promising
choice for both BRCA-mutated and sporadic triple negative breast
cancer. Sci Rep. 7:75052017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kumar S, Eroglu E, Stokes JA III,
Scissum-Gunn K, Saldanha SN, Singh UP, Manne U, Ponnazhagan S and
Mishra MK: Resveratrol induces mitochondria-mediated,
caspase-independent apoptosis in murine prostate cancer cells.
Oncotarget. 8:20895–20908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wen W, Zhu F, Zhang J, Keum YS, Zykova T,
Yao K, Peng C, Zheng D, Cho YY, Ma WY, et al: MST1 promotes
apoptosis through phosphorylation of histone H2AX. J Biol Chem.
285:39108–39116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu J, Cai Y, Xu K, Ren X, Sun J, Lu S,
Chen J and Xu P: Beclin1 overexpression suppresses tumor cell
proliferation and survival via an autophagydependent pathway in
human synovial sarcoma cells. Oncol Rep. 40:1927–1936.
2018.PubMed/NCBI
|
|
27
|
Saitoh Y, Setoguchi T, Nagata M, Tsuru A,
Nakamura S, Nagano S, Ishidou Y, Nagao-Kitamoto H, Yokouchi M,
Maeda S, et al: Combination of Hedgehog inhibitors and standard
anticancer agents synergistically prevent osteosarcoma growth. Int
J Oncol. 48:235–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH,
Lin YF and Shih CM: Resveratrol enhances the therapeutic effect of
temozolomide against malignant glioma in vitro and in vivo by
inhibiting autophagy. Free Radic Biol Med. 52:377–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dosch J, Christmann M and Kaina B:
Mismatch G-T binding activity and MSH2 expression is quantitatively
related to sensitivity of cells to methylating agents.
Carcinogenesis. 19:567–573. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yip S, Miao J, Cahill DP, Iafrate AJ,
Aldape K, Nutt CL and Louis DN: MSH6 mutations arise in
glioblastomas during temozolomide therapy and mediate temozolomide
resistance. Clin Cancer Res. 15:4622–4629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yoon JW, Gilbertson R, Iannaccone S,
Iannaccone P and Walterhouse D: Defining a role for Sonic hedgehog
pathway activation in desmoplastic medulloblastoma by identifying
GLI1 target genes. Int J Cancer. 124:109–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ulasov IV, Nandi S, Dey M, Sonabend AM and
Lesniak MS: Inhibition of sonic hedgehog and notch pathways
enhances sensitivity of CD133+ glioma stem cells to
temozolomide therapy. Mol Med. 17:103–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nasr R, Guillemin MC, Ferhi O, Soilihi H,
Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M,
Lallemand-Breitenbach V, Gourmel B, et al: Eradication of acute
promyelocytic leukemia-initiating cells through PML-RARA
degradation. Nat Med. 14:1333–1342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim J, Lee JJ, Kim J, Gardner D and Beachy
PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary
accumulation and reducing stability of the Gli2 transcriptional
effector. Proc Natl Acad Sci USA. 107:13432–13437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sekulic A, Migden MR, Oro AE, Dirix L,
Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, et al: Efficacy and safety of vismodegib in advanced basal-cell
carcinoma. N Engl J Med. 366:2171–2179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gould SE, Low JA, Marsters JC Jr, Robarge
K, Rubin LL, de Sauvage FJ, Sutherlin DP, Wong H and Yauch RL:
Discovery and preclinical development of vismodegib. Expert Opin
Drug Discov. 9:969–984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chang AL, Solomon JA, Hainsworth JD,
Goldberg L, McKenna E, Day BM, Chen DM and Weiss GJ: Expanded
access study of patients with advanced basal cell carcinoma treated
with the Hedgehog pathway inhibitor, vismodegib. J Am Acad
Dermatol. 70:60–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tomita A, Kiyoi H and Naoe T: Mechanisms
of action and resistance to all-trans retinoic acid (ATRA)
and arsenic trioxide (As2O3) in acute
promyelocytic leukemia. Int J Hematol. 97:717–725. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pricl S, Cortelazzi B, Dal Col V, Marson
D, Laurini E, Fermeglia M, Licitra L, Pilotti S, Bossi P and
Perrone F: Smoothened (SMO) receptor mutations dictate resistance
to vismodegib in basal cell carcinoma. Mol Oncol. 9:389–397. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee PC, Kakadiya R, Su TL and Lee TC:
Combination of bifunctional alkylating agent and arsenic trioxide
synergistically suppresses the growth of drug-resistant tumor
cells. Neoplasia. 12:376–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Melamed JR, Morgan JT, Ioele SA, Gleghorn
JP, Sims-Mourtada J and Day ES: Investigating the role of
Hedgehog/GLI1 signaling in glioblastoma cell response to
temozolomide. Oncotarget. 9:27000–27015. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chou TC: Drug Combination studies and
their synergy quantification using the chou-talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Alves TR, Lima FR, Kahn SA, Lobo D, Dubois
LG, Soletti R, Borges H and Neto VM: Glioblastoma cells: A
heterogeneous and fatal tumor interacting with the parenchyma. Life
Sci. 89:532–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
McDonald K, Joshi S, Jue TR, Yin J and
Khasraw M: ATPS-54genomically Unstable Glioblastoma (U-GBM) show
exquisite sensitivity to parp inhibition. Neuro Oncol. 17:v302015.
View Article : Google Scholar :
|
|
47
|
Shou Y, Robinson DM, Amakye DD, Rose KL,
Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, et al: A
five-gene hedgehog signature developed as a patient preselection
tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer
Res. 21:585–593. 2015. View Article : Google Scholar : PubMed/NCBI
|
